Incyte Stock Drops as Cancer Drug Data Hits: Wall Street Split Remains in Focus
Incyte shares fell 3.5% Tuesday to $92.24 after new data from its frontMIND lymphoma trial, with losses continuing in premarket trading. The Phase 3 study showed adding tafasitamab and lenalidomide to R-CHOP cut risk of progression or death by 25%, but did not reach statistical significance for overall survival. Serious adverse events were more frequent in the combination arm. Analysts remain split on the stock.
